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Background
Cardiac magnetic resonance imaging (CMR) can be used to
determine both myocardial infarct (MI) size and myocar-
dium at risk (MaR), enabling assessment of myocardial
salvage index (MSI). MI size as assessed by hyperenhance-
ment on late gadolinium enhancement (LGE) has been
shown to decrease approximately 25% during the first week
after infarction. The aim of this study was to determine to
what extent assessment of MSI and a narrow inclusion win-
dow affect the number of patients needed to reach sufficient
statistical power in a clinical CMR cardioprotection trial.
Methods
Control subjects (n=91) from the recent CHILL-MI1 and
MITOCARE2 cardioprotection trials, examined by CMR
2-6 days after acute reperfusion therapy, were used to
assess the difference in sample size required to reach suffi-
cient statistical power when using MI size alone compared
to MSI as outcome variable. In addition, 22 patients
undergoing CMR at day 1 and 7 after acute reperfused
infarction from a previous follow-up study3 were included
to assess to what extent sample size is affected by the
decrease in hyperenhancement seen during the first week
after infarction. The variability of MI size by LGE, MaR by
contrast-enhanced SSFP and MSI was used to simulate
100.000 clinical trials for different assumed treatment
effects to determine the number of patients needed to
reach sufficient statistical power.
Results
For an assumed effect of 25 % reduction in MI size by a
cardioprotection treatment, the number of patients
needed to reach sufficient statistical power can be
reduced by 48% (34 patients in each arm versus 65) if
using MSI instead of MI size alone as outcome variable
(Figure 1). If a fixed time point for the CMR examination
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Figure 1 The number of patients needed in each arm to reach sufficient statistical power.
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is used instead of an inclusion window of 1-7 days after
infarction, the number of patients needed to reach suffi-
cient statistical power decreased by 31% for infarct size
alone and 23% for MSI. Figure 2 shows an example of the
reduction of hyperenhancement between day 1 and 7.
Conclusions
There is a significant reduction in sample size needed to
reach sufficient statistical power in CMR cardioprotec-
tion trials when using MSI instead of MI size alone as
outcome variable. In addition, sample size can be further
reduced by narrowing the inclusion window during the
first week after the acute event.
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Figure 2 Change in hyperenhancement (arrows) day 1 and 7 after acute reperfusion therapy in a patient with inferior infarction.
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